Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Hospitals Still Waiting On Promised Discounts For Valeant’s Heart Drugs

XTALKS VITALS NEWS

Drug Pricing

After acquiring Nitropress and Isuprel in February last year, Valeant increased the drugs’ prices by over 300 and 700 percent, respectively.

Share this!

May 16, 2016 | by Sarah Massey, M.Sc.

Early this year, Valeant Pharmaceuticals pledged to offer hospitals up to 30 percent off the list price for their expensive heart medications. Three months later, top heart hospitals – like the Cleveland Clinic – are still waiting for the pharmaceutical company to make good on their promise.

The drugs in question - Nitropress and Isuprel – are commonly used by healthcare facilities to treat patients with heart problems. After acquiring the drugs in 2015, Valeant raised their prices so much that the Cleveland Clinic alone spent $5.3 million on the heart drugs last year.

“I think we definitely would be among the top users,” said Scott Knoer, the chief pharmacy officer at the Cleveland Clinic. “I would assume we would be on that list.”

This situation isn’t unique to the Cleveland Clinic; other large hospitals around the US, including Johns Hopkins, the Mayo Clinic and New York-Presbyterian, have also heard nothing regarding the promised price cuts. Two weeks ago, Valeant’s chief executive pledged to investigate the claim that not one hospitals had received the discounts on the heart drugs, but hospital administrators say nothing has changed.



Valeant said it would offer the discounts through two companies, including Premier, who deal directly with drugmakers to negotiate pricing for hospitals. According to Premier, the discounts were minimal, and only two of its 2,500 member hospitals had received the promised 30 percent price cut. “Valeant, unlike many other companies, has never really been interested in participating in a competitive market,” said a spokeswoman for Premier.

Valeant has generated considerable controversy by employing a business model of buying old drugs and substantially raising their prices. After acquiring Nitropress and Isuprel in February last year, the company increased the drugs’ prices by over 300 and 700 percent, respectively.

In an attempt to repair their image after the drug pricing controversy, Valeant dismissed its CEO, J. Michael Pearson. Valeant’s new CEO, Joseph C. Papa, is reportedly optimistic about unveiling the discount program for the two drugs.

“What we’re now doing is to resolve some of those difficulties that some of the players have experienced,” he said. “I now believe we’ve got a solution to this question, and I look forward to being able to announce this.”


Keywords: Heart Drugs, Drug Pricing, Hospital Pharmacy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News


FDA Approves New Drug for Parkinson’s Disease

March 23, 2017 - Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease.

Featured In: Clinical Trials News, Life Science News, Pharmaceutical News


Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.